Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-25-096895
Filing Date
2025-04-25
Accepted
2025-04-25 16:18:47
Documents
16
Period of Report
2025-06-05

Document Format Files

Seq Description Document Type Size
1 DEF 14A d923242ddef14a.htm   iXBRL DEF 14A 627571
3 GRAPHIC g923242dsp010.jpg GRAPHIC 159399
4 GRAPHIC g923242dsp011.jpg GRAPHIC 120131
5 GRAPHIC g923242g40g40.jpg GRAPHIC 93547
6 GRAPHIC g923242g51i53.jpg GRAPHIC 120550
  Complete submission text file 0001193125-25-096895.txt   2446542

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA svra-20241231.xsd EX-101.SCH 2506
18 EXTRACTED XBRL INSTANCE DOCUMENT d923242ddef14a_htm.xml XML 173494
Mailing Address 6836 BEE CAVE ROAD BUILDING 3, SUITE 201 AUSTIN TX 78746
Business Address 6836 BEE CAVE ROAD BUILDING 3, SUITE 201 AUSTIN TX 78746 51285113796
Savara Inc (Filer) CIK: 0001160308 (see all company filings)

EIN.: 841318182 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-32157 | Film No.: 25874364
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)